Halsey Associates Inc. CT cut its stake in shares of Allergan plc (NYSE:AGN) by 8.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 27,212 shares of the company’s stock after selling 2,431 shares during the period. Halsey Associates Inc. CT’s holdings in Allergan were worth $4,537,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Qube Research & Technologies Ltd purchased a new stake in shares of Allergan during the 2nd quarter worth approximately $404,000. HRT Financial LLC purchased a new stake in Allergan in the 2nd quarter valued at $417,000. Highlander Capital Management LLC raised its position in Allergan by 100.7% in the 2nd quarter. Highlander Capital Management LLC now owns 4,136 shares of the company’s stock valued at $690,000 after purchasing an additional 2,075 shares during the last quarter. Mutual Advisors LLC raised its position in Allergan by 44.1% in the 2nd quarter. Mutual Advisors LLC now owns 2,317 shares of the company’s stock valued at $386,000 after purchasing an additional 709 shares during the last quarter. Finally, Putnam Investments LLC increased its stake in Allergan by 108.8% in the 2nd quarter. Putnam Investments LLC now owns 52,281 shares of the company’s stock valued at $8,717,000 after buying an additional 27,242 shares during the period. Institutional investors and hedge funds own 77.38% of the company’s stock.
Shares of NYSE:AGN opened at $189.63 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. Allergan plc has a 52-week low of $142.81 and a 52-week high of $209.04. The company has a market capitalization of $64.66 billion, a price-to-earnings ratio of 11.60, a PEG ratio of 1.47 and a beta of 1.19.
The company also recently disclosed a quarterly dividend, which was paid on Monday, September 17th. Investors of record on Friday, August 17th were paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.52%. The ex-dividend date was Thursday, August 16th. Allergan’s dividend payout ratio (DPR) is presently 17.61%.
Several equities analysts have issued reports on the stock. Mizuho reissued a “hold” rating and issued a $194.00 price objective on shares of Allergan in a research note on Monday, July 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $180.00 price target on shares of Allergan in a research note on Friday, September 14th. Guggenheim initiated coverage on shares of Allergan in a research note on Monday. They set a “buy” rating on the stock. Zacks Investment Research raised shares of Allergan from a “hold” rating to a “buy” rating and set a $197.00 price objective on the stock in a research note on Wednesday, July 11th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a research note on Monday, June 11th. Two analysts have rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $211.91.
In related news, Director Joseph H. Boccuzi bought 900 shares of the business’s stock in a transaction on Thursday, August 30th. The shares were bought at an average cost of $190.59 per share, for a total transaction of $171,531.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher J. Coughlin bought 10,000 shares of the business’s stock in a transaction on Thursday, September 6th. The stock was bought at an average price of $190.64 per share, for a total transaction of $1,906,400.00. The disclosure for this purchase can be found here. Company insiders own 0.37% of the company’s stock.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Read More: Put Option
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.